| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR MEDICINE |
1 Division of Medicine and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
2 Department of Cardiology, Ninewells Hospital and Medical School, Dundee, UK
Correspondence to:
Correspondence to:
Dr Justine Davies
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; j.i.davies{at}dundee.ac.uk
Objective: To find out whether B-type natriuretic peptide (BNP) detects silent myocardial ischaemia in patients with type 2 diabetes, since many of these patients have silent ischaemia leading to unexpected cardiac deaths.
Design: Prospective cross-sectional study with consecutive recruitment of patients.
Setting: Outpatient, single centre.
Patients: 219 patients with type 2 diabetes. Patients were excluded if they had a history or evidence of cardiac failure.
Outcome measures: BNP, echocardiography and exercise tolerance test (ETT). BNP was compared with the ETT result in all patients and specifically in those who had no apparent ischaemic heart disease (IHD).
Results: 121 patients had no history of IHD or cardiac failure and of these patients 85 had a clearly abnormal or normal ETT result. BNP was higher in patients with an abnormal than with a normal ETT (mean 58.2 (SD 46.3) v 24.4 (SD 15.7) pg/ml, p < 0.001). In univariate analysis BNP was an independent predictor of an abnormal ETT (p < 0.001). In multivariate analysis BNP remained an independent predictor of the ETT result. BNP concentration over 20 pg/ml predicted an abnormal ETT result with a sensitivity of 87% and specificity of 37%, and BNP over 40 pg/ml had a sensitivity of 63% and a specificity of 81%.
Conclusion: BNP is of value in predicting silent ischaemia on exercise testing in asymptomatic patients with type 2 diabetes.
Abbreviations: ACIP, Asymptomatic Cardiac Ischemia Pilot; BNP, B-type natriuretic peptide; ETT, exercise tolerance testing; EUROASPIRE, European action on Secondary Prevention through Intervention to Reduce Events; IHD, ischaemic heart disease; IQR, interquartile range; LV, left ventricular; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index
Keywords: natriuretic peptides; myocardial ischaemia; exercise tolerance testing
This article has been cited by other articles:
|
|
 |
|
  B. Pitt N-terminal pro-B-type natriuretic peptide concentrations >=100 ng/l increased risk of all-cause mortality Evid. Based Med., February 1, 2008; 13(1): 26 - 26. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Pascual-Figal, M. J Antolinos, A. Bayes-Genis, T. Casas, F. Nicolas, and M. Valdes B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans Heart, September 1, 2007; 93(9): 1077 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Struthers and C. Lang The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney Eur. Heart J., July 2, 2007; 28(14): 1678 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Struthers and C. C. Lang Letter by Struthers et al Regarding Article, "Cross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Function" Circulation, September 5, 2006; 114(10): e383 - e383. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
